Summit Therapeutics, Inc. (SMMT)
14.15
-0.92
(-6.14%)
USD |
NASDAQ |
Nov 13, 16:00
11.75
-2.40
(-16.96%)
After-Hours: 04:15
Summit Therapeutics Enterprise Value : 10.71B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 10.71B |
| November 12, 2026 | 11.45B |
| November 11, 2026 | 12.70B |
| November 10, 2026 | 13.65B |
| November 09, 2026 | 13.66B |
| November 06, 2026 | 12.45B |
| November 05, 2026 | 10.74B |
| November 04, 2026 | 12.32B |
| November 03, 2026 | 12.03B |
| November 02, 2026 | 11.23B |
| October 30, 2026 | 12.21B |
| October 29, 2026 | 12.35B |
| October 28, 2026 | 12.00B |
| October 27, 2026 | 11.65B |
| October 26, 2026 | 10.99B |
| October 23, 2026 | 11.76B |
| October 22, 2026 | 11.83B |
| October 21, 2026 | 12.05B |
| October 20, 2026 | 12.26B |
| October 19, 2026 | 11.84B |
| October 16, 2026 | 11.09B |
| October 15, 2026 | 11.68B |
| October 14, 2026 | 11.49B |
| October 13, 2026 | 11.80B |
| October 12, 2026 | 13.09B |
| Date | Value |
|---|---|
| October 09, 2026 | 13.46B |
| October 08, 2026 | 13.12B |
| October 07, 2026 | 13.74B |
| October 06, 2026 | 13.23B |
| October 05, 2026 | 13.20B |
| October 02, 2026 | 12.79B |
| October 01, 2026 | 12.74B |
| September 30, 2026 | 12.91B |
| September 29, 2026 | 12.33B |
| September 28, 2026 | 11.61B |
| September 25, 2026 | 11.71B |
| September 24, 2026 | 12.32B |
| September 23, 2026 | 12.38B |
| September 22, 2026 | 12.91B |
| September 21, 2026 | 12.73B |
| September 18, 2026 | 13.49B |
| September 17, 2026 | 13.38B |
| September 16, 2026 | 13.05B |
| September 15, 2026 | 13.13B |
| September 14, 2026 | 13.94B |
| September 11, 2026 | 13.25B |
| September 10, 2026 | 12.81B |
| September 09, 2026 | 13.24B |
| September 08, 2026 | 13.03B |
| September 04, 2026 | 13.29B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.108M |
| Brainstorm Cell Therapeutics, Inc. | 12.28M |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 27.10M |
| Clene, Inc. | 68.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -208.38M |
| Total Expenses (Quarterly) | 208.38M |
| EPS Diluted (Quarterly) | -0.2611 |
| Earnings Yield | -7.55% |
| Normalized Earnings Yield | -7.551 |